Dogwood Therapeutics (DWTX) Shares Outstanding (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Shares Outstanding (Entity) of $33.4 million for Q1 2026, up 2217.08% year-over-year from $1.4 million in Q1 2025, and up 571.06% quarter-over-quarter from $5.0 million in Q4 2025.
Dogwood Therapeutics (DWTX) Shares Outstanding (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Shares Outstanding (Entity) for 7 consecutive years, with $33.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2217.08% year-over-year to $33.4 million; the TTM figure through Mar 2026 stood at $33.4 million (up 2217.08% YoY), while the FY2025 annual figure was $5.0 million, up 384.29% from the prior year.
- Shares Outstanding (Entity) rose to $33.4 million in Q1 2026 per DWTX's latest filing, from $5.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $33.4 million in Q1 2026 and bottomed at $333216.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $3.1 million across 5 years, with a median of $770317.0 in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) changed 0.0% — and 2026, when it soared 2217.08%.
- Dogwood Therapeutics' Shares Outstanding (Entity) stood at $442805.0 in 2022, then surged by 73.96% to $770317.0 in 2023, then jumped by 33.42% to $1.0 million in 2024, then soared by 384.29% to $5.0 million in 2025, then soared by 571.06% to $33.4 million in 2026.
- Business Quant data shows DWTX's Shares Outstanding (Entity) at $33.4 million in Q1 2026, $5.0 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 34.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.54 Mn |
| Dec 31, 2025 | 4.98 Mn |
| Sep 30, 2025 | 1.92 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 916,032.00 |
| Mar 31, 2024 | 770,317.00 |
| Dec 31, 2023 | 751,072.00 |
| Sep 30, 2023 | 763,750.00 |
| Jun 30, 2023 | 736,456.00 |
| Mar 31, 2023 | 733,216.00 |
| Dec 31, 2022 | 442,805.00 |
| Sep 30, 2022 | 367,998.00 |
| Jun 30, 2022 | 333,216.00 |
| Mar 31, 2022 | 333,216.00 |
| Dec 31, 2021 | 333,172.00 |
| Sep 30, 2021 | 333,216.00 |
| Jun 30, 2021 | 333,216.00 |